血液製剂的全球市场规模:各产品类型，各最终用途，各地区，范围及预测

血液製品的市场规模及预测

2024 年血液製品市场规模价值为 381.6 亿美元，预计到 2031 年将达到 544.3 亿美元，在 2024-2031 年预测期内的复合年增长率为 4.54%。血液相关疾病的盛行率不断上升以及对血液相关产品的需求正在推动血液产品市场的成长。此外，老年人口的增加也大大推动了血液製品市场的成长。全球血液製品市场报告对市场进行了全面的评估。它对关键细分市场、趋势、市场推动因素、阻碍因素、竞争格局以及在市场中发挥关键作用的因素进行了全面的分析。

全球血液製品市场的定义

血液製品是从捐赠者体内提取并输给患者的血液成分或部分。并非所有患者都需要输全血；许多患者只需要输注血液中的某些成分。为了适应这些情况，某些血液成分被从全血中分离出来。血液产品包括血小板、红血球 (RBC)、白血球 (WBC)、新鲜冷冻血浆 (FFP)、凝血因子等。根据您的症状，我们将给您注射特定的血液製品。

血液是人体必需的连接液体，为身体器官提供营养和氧气。血液製品分为血液成分製品及血浆製品。血液成分包括红血球、冷沉淀和新鲜冷冻血浆，而血浆成分包括白蛋白、凝血因子和免疫球蛋白。血浆衍生产品受《药品事务法》管辖，必须由执业医师开立处方，因为现在全血输血很少见，而血液成分在给患者输血时变得更加重要。

血液的每个成分都必须在相同的条件下储存，例如红血球必须在冰箱的特定温度下储存。根据血液安全和品质法规，采集的血液必须以可读和条码格式标记适当的资讯。从捐赠者身上抽取 405-495 毫升血液，放入 63 毫升柠檬酸磷酸盐葡萄糖和抗凝血剂。捐赠的全血经过过滤以去除白血球。

全球血液製品市场概况

白血病、癌症、末期肾衰竭等血液疾病的发生率增加，其他需要输血的疾病也需要输血，此外，创伤和任何促使大量出血的严重损伤也需要输血。此外，血液製品市场受到主要市场参与者的推动，这些参与者提供实验室试剂、筛检设备以及对捐赠血液进行检测的系统。

此外，全球老年人口的增加以及政府对血液筛检的措施和法规预计将促进血液製品市场的发展。此外，大众对捐血的认知也是加速市场成长的因素之一。另一方面，先进血液采集的高成本和熟练实验室技术人员的短缺限制了血液製品市场的成长。

目录

第1章 全球血液製剂市场简介

• 市场概要
• 调查范围
• 前提条件

第2章 摘要整理

第3章 VERIFIED MARKET RESEARCH的调查手法

• 资料探勘
• 验证
• 第一手资料
• 资料来源一览

第4章 全球血液製剂市场展望

• 概要
• 市场动态
  • 促进因素
  • 阻碍因素
  • 机会
• 波特的五力分析
• 价值链分析

第5章 血液製剂的全球市场:各产品类型

• 概要
• 血小板
• 新鲜冻结血浆(FFP)
• 红血球
• 白血球(WBC)
• 其他

第6章 血液製剂的全球市场:各最终用途

• 概要
• 医院
• 血液站
• 其他

第7章 血液製剂的全球市场:各地区

• 概要
• 北美
  • 美国
  • 加拿大
  • 墨西哥
• 欧洲
  • 德国
  • 英国
  • 法国
  • 其他欧洲
• 亚太地区
  • 中国
  • 日本
  • 印度
  • 其他亚太地区
• 全球其他地区
  • 南美
  • 中东·非洲

第8章 全球血液製剂市场竞争情形

• 概要
• 各公司的市场排行榜
• 主要的发展策略

第9章 企业简介

• CSL
• Octapharma AG
• Kedrion S.p.A
• Mitsubishi Tanabe Pharma Corporation
• BPL Inc.

第10章 主要发展

• 产品上市/开发
• 合併和收购
• 事业扩大
• 伙伴关係和合作

第11章 附录

• 相关调查

Blood Product Market Size And Forecast

Blood Product Market size was valued at USD 38.16 Billion in 2024 and is projected to reach USD 54.43 Billion by 2031, growing at a CAGR of 4.54% during the forecast period 2024-2031. The growing prevalence of blood-related disorders and demand for blood-related products are boosting the growth of the Blood Product Market. In addition, the increasing geriatric population is prominently driving the growth of the Blood Product Market. The Global Blood Product Market report provides a holistic evaluation of the market. The report offers a comprehensive analysis of key segments, trends, drivers, restraints, competitive landscape, and factors that are playing a substantial role in the market.

Global Blood Product Market Definition

Blood Product is any component or part of blood that is collected from a donor for substituting the same in patients. Not every patient requires a transfusion of whole blood, many only require certain components of blood for transfusion. To meet such cases, several blood components are separated from the whole blood. The blood products include platelets, red blood cells (RBCs), white blood cells (WBCs), fresh frozen plasma (FFP), clotting factors, and many others. Depending on the condition, an individual is administered a particular blood product.

Blood is an essential connective fluid of the body that supplies nutrients and oxygen to the organs of the body. Blood products are classified as blood components and plasma-derived products. Blood components include red cells, cryoprecipitate, and fresh frozen plasma while plasma components include albumin, coagulation factors, and immunoglobulin. Plasma derivatives come under the medicines act, which must be prescribed by licensed practitioners as whole blood transfusion is rare now, and blood components are making more sense while transferring to the patient.

Each component of blood must be stored under identical conditions such as red blood cells must be stored in the refrigerator at a specified temperature. as per blood safety and quality, regulation collected blood must be labeled with appropriate information that must be in readable form and barcoded form. 405-495mL of blood can be collected from one donor and then it is collected in 63 mL of citrate phosphate dextrose ad anticoagulant. All donated whole blood was filtered to remove white blood cells.

What's inside a VMR industry report?

Our reports include actionable data and forward-looking analysis that help you craft pitches, create business plans, build presentations and write proposals.

Global Blood Product Market Overview

Blood is an essential component of the body. increasing blood disorders and other medical conditions such as leukemia, cancer, and the end stage of renal disorders require blood transfusion other than this, trauma and any kind of serious injury in which there is huge blood loss demand blood transfusion.in addition, some major surgeries also lead to blood loss thus, there has been more demand for blood and plasma components. Furthermore, the Blood Product Market is prominently driven by key market players that offers reagent for testing, and screening devices along with a system to perform a test of blood that is being donated.

Moreover, the increasing geriatric population across the globe and government initiatives and regulations for blood screening are anticipated to boost the Blood Product Market. Also, awareness about blood donation among people is another factor responsible for accelerating market growth. On the other side, the high cost associated with advanced blood collection and the lack of skilled laboratory people is restricting the growth of the Blood Product Market.

Global Blood Product Market: Segmentation Analysis

The Global Blood Product Market is segmented on the basis of Product Type, End-Use, and Geography.

Blood Product Market, By Product Type

• Platelets
• Fresh Frozen Plasma (FFP)
• Red Blood Cells (RBCs)
• White Blood Cells (WBCs)
• Others

Based on Product Type, the market is bifurcated into Platelets, Fresh Frozen Plasma (FFP), Red Blood Cells (RBCs), White Blood Cells (WBCs), and Others. The red blood cell segment is expected to hold the largest share in the market as it is given to newborns, sickle cell anemia patients, and emergency transfusions during pregnancy, trauma patients. Increasing such medical conditions is driving the growth of the market.

Blood Product Market, By End-Use

• Hospital
• Blood Station
• Others

Based on End-Use, the market is bifurcated into Hospital, Blood Station, and Others. Blood station is expected to hold the largest market share due to a surge in the number of blood station and a large amount of blood is received in blood station by donors. in addition, the rise in the demand for blood and plasma is driving the demand for blood components.

Blood Product Market, By Geography

• North America
• Europe
• Asia Pacific
• Rest of the world
• On the basis of Geography, The Global Blood Product Market is classified into North America, Europe, Asia Pacific, and Rest of the world. The largest share in the market will be dominated by North America Blood Product Market growth in North America is driven by many factors such as the easy availability of reagents, consumables, and systems required for blood collection and the rise in awareness of blood donation in the region.

Key Players

• The "Global Blood Product Market" study report will provide valuable insight with an emphasis on the global market. The major players in the market are
• CSL, Octapharma AG, Kedrion S.p.A, Mitsubishi Tanabe Pharma Corporation, and BPL Inc.

Our market analysis also entails a section solely dedicated to such major players wherein our analysts provide an insight into the financial statements of all the major players, along with its product benchmarking and SWOT analysis. The competitive landscape section also includes key development strategies, market share, and market ranking analysis of the above-mentioned players globally.

Key Developments

• Partnerships, Business Expansion, and Product Launch
• In Dec 2020, CSL Behring enters into a collaboration agreement with Biopole. The collaboration aims to connect the Biopole ecosystem and its start-ups to this global biotechnology. CSL and its REI team will highlight their key goal of increasing global collaboration on external early projects to feed and support growth through this partnership.
• In March 2021, Mitsubishi Tanabe Pharma America, Inc. (MTPA) recently announced that Mitsubishi Tanabe Pharma Holdings America, Inc. (MTHA) intends to establish a new NeuroDiscovery Lab in Cambridge, Mass., a biotechnology hub in the United States. The research facility will serve as a North American hub for identifying and collaborating on precision medicine and new drug development for central nervous system (CNS) diseases, specifically amyotrophic lateral sclerosis (ALS).
• In Aug 2021, BPL Introduces An Innovative Line Of Smartly Designed Consumer Electronics Intended To Satisfy Even The Most Strict Customers.
• In Aug 2021, Reliance Retail will manufacture BPL and Kelvinator products. Reliance Retail has obtained the right to manufacture and sell consumer durable goods under the BPL and Kelvinator brands. The move will also allow Reliance Retail to enter the electrical market, and the agreement with BPL will be announced soon, while the agreement with Kelvinator has already been announced.
• Mergers and Acquisitions
• In Jan 2022, Kedrion will be acquired by Permira, which has merged with BPL and plans to take a minority stake in the combined company.

TABLE OF CONTENTS

1 INTRODUCTION OF GLOBAL BLOOD PRODUCT MARKET

• 1.1 Overview of the Market
• 1.2 Scope of Report
• 1.3 Assumptions

2 EXECUTIVE SUMMARY

3 RESEARCH METHODOLOGY OF VERIFIED MARKET RESEARCH

• 3.1 Data Mining
• 3.2 Validation
• 3.3 Primary Interviews
• 3.4 List of Data Sources

4 GLOBAL BLOOD PRODUCT MARKET OUTLOOK

• 4.1 Overview
• 4.2 Market Dynamics
  • 4.2.1 Drivers
  • 4.2.2 Restraints
  • 4.2.3 Opportunities
• 4.3 Porters Five Force Model
• 4.4 Value Chain Analysis

5 GLOBAL BLOOD PRODUCT MARKET, BY PRODUCT TYPE

• 5.1 Overview
• 5.2 Platelets
• 5.3 Fresh Frozen Plasma (FFP)
• 5.4 Red Blood Cells (RBCs)
• 5.5 White Blood Cells (WBCs)
• 5.6 Others

6 GLOBAL BLOOD PRODUCT MARKET, BY END-USE

• 6.1 Overview
• 6.2 Hospital
• 6.3 Blood Station
• 6.4 Others

7 GLOBAL BLOOD PRODUCT MARKET, BY GEOGRAPHY

• 7.1 Overview
• 7.2 North America
  • 7.2.1 U.S.
  • 7.2.2 Canada
  • 7.2.3 Mexico
• 7.3 Europe
  • 7.3.1 Germany
  • 7.3.2 U.K.
  • 7.3.3 France
  • 7.3.4 Rest of Europe
• 7.4 Asia Pacific
  • 7.4.1 China
  • 7.4.2 Japan
  • 7.4.3 India
  • 7.4.4 Rest of Asia Pacific
• 7.5 Rest of the World
  • 7.5.1 Latin America
  • 7.5.2 Middle East and Africa

8 GLOBAL BLOOD PRODUCT MARKET COMPETITIVE LANDSCAPE

• 8.1 Overview
• 8.2 Company Market Ranking
• 8.3 Key Development Strategies

9 COMPANY PROFILES

• 9.1 CSL
  • 9.1.1 Overview
  • 9.1.2 Financial Performance
  • 9.1.3 Product Outlook
  • 9.1.4 Key Developments
• 9.2 Octapharma AG
  • 9.2.1 Overview
  • 9.2.2 Financial Performance
  • 9.2.3 Product Outlook
  • 9.2.4 Key Developments
• 9.3 Kedrion S.p.A
  • 9.3.1 Overview
  • 9.3.2 Financial Performance
  • 9.3.3 Product Outlook
  • 9.3.4 Key Developments
• 9.4 Mitsubishi Tanabe Pharma Corporation
  • 9.4.1 Overview
  • 9.4.2 Financial Performance
  • 9.4.3 Product Outlook
  • 9.4.4 Key Developments
• 9.5 BPL Inc.
  • 9.5.1 Overview
  • 9.5.2 Financial Performance
  • 9.5.3 Product Outlook
  • 9.5.4 Key Developments

10 KEY DEVELOPMENTS

• 10.1 Product Launches/Developments
• 10.2 Mergers and Acquisitions
• 10.3 Business Expansions
• 10.4 Partnerships and Collaborations

11 Appendix

• 11.1 Related Research